Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report [0.03%]
巨大合并寡转移型肝细胞癌接受多模式治疗(包括放射治疗)后的长期生存案例报告
Byung Min Lee,Jinsil Seong
Byung Min Lee
The clinical efficacy of local ablative treatment for oligometastasis is widely accepted in most cancers. However, due to limited data, this has not been the case for hepatocellular carcinoma (HCC). Here, we report a case of pulmonary oligo...
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma [0.03%]
核苷(酸)类似物对乙型肝炎病毒相关性肝细胞癌经动脉化疗栓塞及射频消融疗效的影响
Jae Min Park,Won Hyeok Choe,Jeong Han Kim et al.
Jae Min Park et al.
Background/aims: Because hepatitis B virus (HBV) replication has been known to play an important role in cancer recurrence after curative treatment of HBV-related hepatocellular carcinoma (HCC), we examined whether treatm...
Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis [0.03%]
肝癌伴门静脉瘤栓的肝脏移植治疗
Sang Jin Kim,Jong Man Kim
Sang Jin Kim
Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments hav...
Primary multifocal cystic signet ring neuroendocrine tumor of liver: a case report [0.03%]
肝原发多灶性囊性黏液癌旁神经内分泌肿瘤1例报告
Nalini Bansal,Brahmananda Satapathy
Nalini Bansal
Primary signet ring neuroendocrine tumors of the liver are extremely rare tumors. Morphologically, they mimic signet ring cell adenocarcinomas; however, the absence of mucin by special stains and the expression of neuroendocrine markers hel...
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report [0.03%]
nivolumab治愈的肝癌合并多发肺转移一例报告
Ji Eun Han,Hyo Jung Cho,Soon Sun Kim et al.
Ji Eun Han et al.
The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivoluma...
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment [0.03%]
晚期肝细胞癌系统治疗的选择及二线治疗的考虑因素
Bo Hyun Kim,Joong-Won Park
Bo Hyun Kim
Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almos...
A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy [0.03%]
肝动脉介入治疗和放射治疗门静脉癌栓的肝细胞癌1例
Jin Yong Lee,Jeong-Ju Yoo,Seong Joon Chun et al.
Jin Yong Lee et al.
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Additionally, hepatic arterial infusion chemotherapy has been used as a treatment option for advanced HCC. Here, we report a ...
Case Reports
Journal of liver cancer. 2020 Mar;20(1):78-83. DOI:10.17998/jlc.20.1.78 2020
Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review [0.03%]
索拉非尼治疗的肝细胞癌患者的冠状动脉反复痉挛1例及文献复习
Dae Hyun Lim,Jai Hoon Yoon,Dae Won Jun et al.
Dae Hyun Lim et al.
Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for variou...
Case Reports
Journal of liver cancer. 2020 Mar;20(1):67-71. DOI:10.17998/jlc.20.1.67 2020
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure [0.03%]
纳武单抗治疗索拉非尼失败后晚期肝细胞癌肺多发转移患者
Jaewoong Kim,Jin Won Chang,Jun Yong Park
Jaewoong Kim
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line therapy t...
Case Reports
Journal of liver cancer. 2020 Mar;20(1):72-77. DOI:10.17998/jlc.20.1.72 2020
Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection [0.03%]
肝切除术后复发的巨大肝细胞癌的经动脉化疗栓塞与外照射治疗联合应用
Jesang Yu,Jinhong Jung,Sang Min Yoon
Jesang Yu
The optimal treatment strategy for unresectable huge hepatocellular carcinoma (HCC) is yet to be established. Non-surgical monotherapy demonstrated insufficient oncologic outcomes in previously reported studies. To improve the clinical outc...
Case Reports
Journal of liver cancer. 2020 Mar;20(1):90-97. DOI:10.17998/jlc.20.1.90 2020